Oppenheimer Maintains Outperform on Soleno Therapeutics, Lowers Price Target to $80

Benzinga Newsdesk www.benzinga.com Negative 91.3%

Neg 91.3% Neu 0% Pos 0%

Oppenheimer analyst Leland Gershell maintains Soleno Therapeutics (NASDAQ:SLNO) with a Outperform and lowers the price target from $110 to $80.